Avcilar

Researchers are studying how mobile-based education affects women undergoing surgery for gynecological cancer. The study aims to see if this education can improve symptom control and enhance quality of life after surgery. It is a randomized controlled experimental design conducted by Istanbul University - Cerrahpasa. Women participating will be randomly divided into two groups an experimental group receiving education through a specially developed mobile care support application, and a control group that will have no intervention aside from data collection. The study plans to include about 70 women, with 35 in each group, and will use several questionnaires and forms to collect data. Participants will be assessed two weeks after surgery using quality of life and symptom control measures. Data will be analyzed to compare changes between and within groups. The study involves completing forms like the Functional Assessment of Cancer Therapy-General and usability questionnaires to evaluate the mobile application. All data will be analyzed statistically to determine the impact of the education.

Researchers are evaluating how a new combination treatment of Sigvotatug Vedotin plus pembrolizumab works compared to pembrolizumab alone in adults with non-small cell lung cancer NSCLC who have high levels of the PD-L1 protein. This protein can limit the bodys immune response to cancer. The study includes participants with advanced NSCLC who meet specific molecular and staging criteria and aims to assess the treatments effects on survival and disease progression. Participants receive pembrolizumab as an intravenous infusion once every 6 weeks at the clinic. Half of the participants will also receive Sigvotatug Vedotin intravenously every 2 weeks alongside pembrolizumab. Pembrolizumab treatment may continue for up to about two years, whereas Sigvotatug Vedotin administration can continue until the cancer no longer responds. The trial is randomized and controlled, comparing the combination treatment to pembrolizumab alone. During the study, participants attend regular clinic visits for treatment and monitoring. Researchers will evaluate overall survival and progression-free survival over approximately two years, along with additional measures such as response rates, duration of response, safety, and drug levels in the blood. The study includes ongoing assessments to observe how participants respond to treatment and manage side effects, with a total participation time that may extend up to several years.